arthralgia
arthriti
current
specif
vaccin
effect
antivir
avail
antichikv
phosphorodiamid
morpholino
oligom
cpmo
evalu
antivir
efficaci
cytotoxc
human
cell
neonat
murin
model
two
cpmo
design
block
translat
initi
highli
conserv
sequenc
chikv
nonstructur
structur
polyprotein
respect
pretreat
hela
cell
signficantli
suppress
chikv
titr
chikv
protein
express
prevent
chikvinduc
cpe
activ
also
chikvspecif
shown
lack
crossreact
sinv
denv
replic
administ
prophylact
neonat
mice
confer
surviv
chikv
diseas
parallel
mice
demonstr
signific
reduct
viremia
viral
load
variou
tissu
immunohistolog
examin
skelet
muscl
liver
mice
also
show
healthi
tissu
morpholog
contrast
evid
manifest
chikv
pathogenesi
pbsor
scrambl
group
taken
togeth
find
highlight
first
time
strong
protect
effect
chikv
infect
warrant
futur
develop
morpholino
altern
antivir
agent
address
chikv
infect
clinic
applic
scientif
report
doi
shown
effect
chikv
replic
cultur
cell
anim
model
howev
drug
show
limit
success
human
clinic
trial
pharmacosafeti
promis
host
specif
compound
chikv
replic
yet
investig
vivo
live
attenu
chikv
vaccin
still
need
clinic
evalu
regard
press
concern
develop
highli
safe
potent
therapeut
altern
chikv
diseas
chikv
envelop
rna
viru
contain
singlestrand
positivesens
kb
rna
genom
alphaviru
viral
genom
rna
consist
two
open
read
frame
orf
follow
receptormedi
endocytosi
chikv
host
cell
viru
mediat
mediat
synthesi
posit
negativestrand
viral
rna
protein
first
orf
chikv
genom
rna
translat
nonstructur
polyprotein
consequ
posttransl
cleav
nonstructur
protein
nonstructur
protein
form
replic
complex
requir
drive
synthesi
subgenom
rna
translat
initi
second
orf
chikv
subgenom
rna
lead
format
structur
protein
name
capsid
togeth
newlyrepl
viral
rna
structur
protein
matur
virion
form
releas
given
viru
replic
depend
viral
rna
synthesi
antisens
oligom
target
specif
viral
rna
sequenc
effect
strategi
inhibit
viru
replic
recent
advanc
antisens
technolog
phosphorodiamid
morpholino
oligom
pmo
highli
effici
block
cellular
gene
express
pmo
singlestrand
oligonucleotid
made
novel
sixmemb
morpholin
ring
purin
pyrimidin
base
link
uniqu
phosphorodiamid
bond
high
affinitybind
complementari
sequenc
translat
region
pmo
form
steric
block
ribosom
assembl
target
rna
molecul
prevent
rna
translat
pmomedi
inhibit
wide
demonstr
cell
cultur
infect
dengu
viru
denv
west
nile
viru
wnv
multipl
strain
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
enteroviru
well
alphaviru
member
sindbi
viru
sinv
venezuelan
equin
enceph
viru
veev
murin
model
pmo
also
strongli
protect
wnv
influenza
viru
veev
japanes
enceph
viru
respiratori
syncyti
viru
ebola
viru
infect
notabl
pmo
therapeut
also
success
reach
human
clinic
trial
prospect
promis
antivir
efficaci
antichikv
pmo
name
design
target
sequenc
aug
region
first
second
orf
chikv
rna
genom
prevent
translat
initi
nonstructur
structur
protein
respect
thu
inhibit
chikv
replic
antivir
efficaci
evalu
viral
plaqu
assay
western
blot
detect
viral
protein
express
ultrastructur
analysi
viru
titrat
immunohistolog
analysi
mice
organ
well
mice
surviv
studi
find
collect
show
highli
potent
chikv
replic
cellbas
murin
model
chikv
effect
construct
effici
uptak
cpmo
absenc
cellular
cytotox
studi
design
bind
aug
region
chikv
genom
rna
respect
fig
cpmo
target
sequenc
structur
access
complex
secondari
fold
fig
sequenc
also
predict
highli
conserv
among
differ
geograph
strain
chikv
fig
tabl
quantif
cell
viabil
done
follow
incub
combin
pmo
endoport
ep
deliveri
reagent
ep
individu
cpmo
confluent
hela
cell
least
h
cell
remain
viabl
across
pmo
ep
concentr
rang
h
posttreat
supplementari
figur
consist
cell
viabliti
also
close
ep
control
treatment
supplementari
figur
least
observ
cpmo
treatment
h
h
h
posttreat
fig
taken
togeth
suggest
ep
deliveri
design
cpmo
combin
appar
toxciti
hela
cell
order
visual
cpmo
intracellular
distribut
follow
cellular
uptak
cell
incub
fluoresceinatedcpmo
ep
h
stain
dapi
dye
observ
fluoresc
microscopi
none
mocktreat
eptreat
cell
visibl
fluoresc
signal
fitc
channel
fig
c
contrast
cell
show
diffus
fluoresc
occur
individu
freeli
cluster
around
cytosol
therebi
suggest
effici
epmedi
cellular
uptak
cpmo
next
cpmotreat
cell
subject
chikv
infect
moi
attempt
investig
whether
intracellular
stabil
cpmo
affect
postchikv
infect
fluoresc
signal
similarli
detect
least
chikvinfect
cell
day
pi
fig
similar
posttreat
cpmo
signal
locat
cell
cytosol
coloc
chikv
protein
stain
suggest
cpmo
could
distribut
endoplasm
reticulum
inhibit
chikv
protein
express
though
cpmo
signal
compar
reduc
day
pi
remain
intracellularli
stabl
among
chikvinfect
cell
observ
evid
fluoresc
signal
signific
reduct
chikv
titr
viral
protein
level
cell
pretreat
hela
cell
target
synthesi
chikv
nonstructur
polyprotein
target
synthesi
structur
polyprotein
chikv
infect
carri
moi
viru
titr
cultur
supernat
quantit
viral
plaqu
assay
postinfect
timepoint
day
chosen
base
chikv
growth
kinet
hela
cell
highest
chikv
titr
produc
day
pi
supplementari
figur
mock
ep
scpmo
treatment
produc
similarli
high
level
chikv
titr
day
pi
fig
rel
mocktreat
bind
sequenc
upstream
first
open
read
frame
orf
encod
nonstructur
protein
target
sequenc
second
orf
import
express
capsid
c
structur
protein
structur
protein
requir
format
matur
chikv
virion
black
arrow
indic
translat
initi
secondari
structur
cpmo
target
region
chikv
genom
predict
mfold
program
http
mfoldrnaalbanyedu
q
mfoldrnafoldingform
cpmo
conjug
carboxyflurocesin
tag
oval
end
aug
translat
start
site
outlin
box
target
site
appear
access
compar
b
ncbi
blast
nucleotid
align
repres
geograph
strain
chikv
show
high
similar
cpmo
target
sequenc
except
mismatch
base
cpmo
antichikv
phosophorodiamid
morpholino
oligom
denot
match
nucleotid
base
control
significantli
reduc
chikv
titr
log
pfuml
day
pi
log
pfu
ml
day
pi
contrast
pretreat
equal
concentr
achiev
log
pfuml
reduct
chikv
titr
day
pi
parallel
quantif
viru
titr
total
cell
lysat
cpmo
scpmo
treatedcel
harvest
three
day
pi
western
blot
detect
chikv
protein
express
level
mock
ep
scpmotreat
cell
increas
level
express
chikv
fig
c
protein
fig
e
observ
day
day
pi
correl
increas
viru
titr
fig
hand
viral
protein
level
almost
complet
suppress
day
pi
cell
pretreat
similarli
cell
show
strong
reduct
protein
express
rel
chikvinfect
control
fig
howev
treatment
seem
less
effect
silenc
product
protein
infecti
chikv
titr
rel
taken
togeth
find
highlight
strong
antivir
efficaci
chikv
replic
interest
whether
specif
inhibitori
effect
chikv
per
se
carri
similar
treatment
assay
hela
cell
subject
sindbi
viru
sinv
dengu
viru
denv
infect
moi
day
pi
sinv
use
studi
belong
togavirida
famili
similar
chikv
denv
repres
member
flavivirus
quantif
viru
titr
viral
plaqu
assay
demonstr
signific
differ
sinv
denv
titr
rel
mocktreat
cell
fig
g
support
data
homolog
align
target
sequenc
chikv
rna
genbank
sinv
genbank
denv
genom
genbank
reveal
signific
similar
data
shown
therefor
deduc
highli
specif
chikv
crossreact
replic
alphavirus
flavivirus
valid
efficaci
transmiss
electron
microscopi
tem
carri
day
postinfect
cell
ultrastructur
observ
chikv
replic
mockinfect
hela
cell
maintain
healthi
cellular
morpholog
intact
organel
welldefin
nucleu
mitochondria
endoplasm
reticulum
fig
cell
surfac
membran
smooth
sign
chikv
virion
chikvinfect
fig
ep
fig
cell
fig
extens
viru
replic
occur
indic
format
numer
chikv
replic
complex
name
cytopath
vacuol
type
ii
cpvii
arrowhead
cytosol
fig
late
phase
chikv
replic
infect
cell
show
assembl
bud
matur
chikv
virion
cell
surfac
intercellular
junction
fig
e
f
contrast
cell
show
sign
chikv
replic
absenc
cpv
say
pi
fig
h
mitochondria
endoplasm
reticulum
remain
intact
viru
bud
cell
surfac
cell
junction
similar
mocktreat
cell
fig
ultrastructur
analysi
strengthen
find
treatment
hela
cell
effect
prevent
chikv
infect
within
cell
shown
could
strongli
suppress
cellular
chikv
replic
assess
antivir
efficaci
suitabl
murin
model
old
balbc
mice
previous
establish
chikv
infect
research
laboratori
old
balbc
model
mice
succumb
chikv
infect
rang
lethal
day
pi
rel
mockinfect
wildtyp
control
group
could
variabl
surviv
due
develop
innat
immun
help
mice
overcom
lethal
therefor
notabl
use
mous
model
analyz
acut
phase
chikv
infect
latter
wellcharacter
high
viremia
viru
burden
pathogenesi
chikvtarget
tissu
includ
hind
limb
muscl
liver
spleen
brain
data
shown
studi
vivopmo
name
scrambl
synthes
fluoresc
dye
replac
octaguanidium
dendrim
mediat
effect
vivo
deliveri
mice
tissu
follow
administr
via
intraperiton
ip
inject
gg
murin
model
serum
lactat
dehydragenas
ldh
level
mice
remain
low
insignific
compar
ldh
posit
control
activ
ldh
commonli
use
stabl
biomark
cytotox
assay
base
find
infer
absenc
dosedepend
toxic
vivopmo
treatment
fig
next
antivir
efficaci
gg
gg
investig
compound
administ
mice
two
consecut
day
follow
chikv
infect
subsequ
treatment
two
consecut
dose
h
h
pi
doseinhibit
effect
observ
gg
protect
mice
chikvinduc
morbid
gg
enhanc
surviv
mice
two
week
pi
fig
contrast
pbsand
control
group
show
surviv
day
pi
surviv
day
pi
respect
averag
daili
basi
gg
also
confer
mice
healthi
weight
gain
similar
mockinfect
mice
gg
mice
show
retard
growth
similar
pbsand
group
fig
mous
model
provid
evalu
absolut
lethal
quantif
chikv
titr
mice
serum
sever
organ
evalu
day
pi
analyz
protect
efficaci
acut
phase
chikv
infect
inde
strong
suppress
chikv
product
variou
tissu
mice
rel
pbsand
group
fig
line
high
potenc
protect
seen
surviv
studi
given
gg
notabl
reduct
viremia
log
fig
chikv
load
spleen
log
fig
liver
log
fig
brain
log
fig
limb
log
fig
taken
togeth
data
show
statist
analysi
perform
use
oneway
anova
across
group
follow
unpair
onetail
ttest
p
p
administr
gg
strongli
protect
chikv
diseas
murin
model
acut
phase
valid
antivir
activ
chikv
diseas
develop
mice
histolog
analysi
perform
pb
mice
tissu
day
pi
pbstreat
chikv
infect
mice
tissu
show
evid
morpholog
abnorm
line
studi
chikv
muscl
tropism
limb
muscl
fibr
pbsor
chikvinfect
mice
show
degen
chang
form
diffus
necrosi
extens
infiltr
variou
immun
cell
lymphocyt
neutrophil
fig
e
suggest
inflamm
occur
skelet
muscl
fibr
due
chikv
pathogenesi
liver
tissu
mice
also
show
nuclei
inclus
pale
necrot
hepatocyt
indic
chikvinduc
morpholog
damag
fig
f
contrast
muscl
liver
tissu
gg
mice
retain
healthi
integr
protect
chikv
pathogenesi
fig
h
similar
mocktreat
mice
fig
b
respect
parallel
find
h
e
examin
immunohistochem
ihc
analysi
show
posit
intens
chikv
antigen
stain
limb
muscl
liver
pbstreat
mice
day
pi
pb
group
chikv
antigen
wide
distribut
along
epimysium
skelet
muscl
fig
viral
antigen
stain
appear
like
granul
structur
cytoplasm
hepatocyt
fig
n
close
associ
degener
necrosi
hepatocyt
shown
h
e
stain
fig
f
contrast
mice
strongli
protect
chikv
antigen
muscl
liver
tissu
fig
p
summari
histolog
examin
visual
valid
find
thu
far
strongli
protect
chikv
replic
mice
follow
chikv
infect
studi
pmo
investig
inhibitori
efficaci
chikv
replic
human
cell
murin
model
previou
studi
util
small
hairpin
rna
shrna
construct
demonstr
strong
potenti
antisens
molecul
suppress
chikv
replic
hela
cell
howev
treatmentinduc
toxic
high
suscept
sirna
intracellular
degrad
pose
limit
further
develop
shrna
preclin
applic
regard
improv
antisens
technolog
desir
biochem
characterist
requir
pmo
neutral
dnalik
oligom
made
nonion
phosphorodiamid
backbon
uniqu
construct
allow
pmo
possess
high
cellular
stabil
excel
safeti
profil
studi
design
two
pmo
target
chikv
rna
genom
evalu
toxic
inhibitori
effect
chikv
replic
vitro
vivo
found
cpmo
exert
cytotox
effect
hela
cell
intraperiton
ip
administr
highest
dose
gg
establish
murin
model
old
neonat
balbc
mous
also
show
absenc
pmoinduc
toxic
lack
behaviour
abnorm
similarli
safe
pharmacolog
profil
pmo
cell
cultur
mice
also
observ
pmo
studi
flavivirus
replic
enhanc
vivo
deliveri
evalu
neonat
antichikv
vivopmo
scrambl
vivopmo
gg
gg
gg
consecut
seven
day
everi
h
interv
mice
sacrif
h
last
treatment
whole
blood
harvest
quantif
ldh
activ
level
b
surviv
studi
two
dose
steril
pb
gg
gg
given
via
ip
neonat
mice
n
per
group
h
interv
follow
chikv
infect
pfu
treatment
given
two
equival
dose
h
pi
h
pi
mice
monitor
daili
sign
symptom
chikv
morbid
well
c
daili
weight
gain
two
week
end
two
week
pi
number
surviv
mice
record
present
kaplanmei
chart
dosedepend
protect
observ
mice
rel
pbsand
group
dh
mice
n
per
group
subject
treatment
regimen
h
pi
whole
blood
e
spleen
f
liver
g
brain
h
hind
limb
harvest
homogen
viral
plaqu
assay
signific
reduct
viremia
chikv
load
observ
statist
analysi
done
use
oneway
anova
across
group
follow
unpair
onetail
ttest
p
p
p
graphpad
prism
scientif
report
doi
murin
model
conjug
octaguanidinium
dendrim
argininerich
peptid
wellvalid
excel
system
deliveri
vivomorpholino
widearray
mice
tissu
albeit
reduc
penetr
abil
brain
due
low
permeabl
bloodbrain
barrier
observ
signific
reduct
chikv
load
liver
spleen
skelet
muscl
well
brain
follow
ip
treatment
suggest
could
favor
taken
organ
therefor
prophylact
protect
tissu
chikv
replic
strengthen
specul
investig
biodistribut
use
bioanalyt
tool
carri
base
previou
studi
hela
cell
wellestablish
highli
permiss
chikv
entri
replic
thu
studi
hela
cell
appropri
human
cell
model
address
figur
histolog
analysi
mice
pretreat
balbc
mice
old
n
ip
inject
gg
chikv
infect
treatment
regimen
carri
aforement
fig
mice
sacrif
day
pi
hind
limb
liver
harvest
fix
formalin
ethanoldehydr
paraffin
embed
section
ah
h
e
stain
ip
ihc
stain
use
primari
rabbit
antichikv
igg
follow
secondari
goat
antirabbit
hrp
igg
efficaci
cpmo
chikv
replic
addit
cpmo
could
broadspectrum
activ
target
highli
conserv
aug
region
sequenc
among
chikv
strain
differ
lineag
furthermor
chikvspecif
crossreact
sinv
denv
replic
strong
efficaci
suppress
chikv
replic
hela
cell
demonstr
collect
viral
plaqu
assay
western
blot
analysi
ultrastructur
analysi
contrast
caus
reduct
log
pfuml
chikv
titr
fig
b
could
attribut
differ
cpmo
target
sequenc
earli
stage
chikv
replic
nonstructur
protein
form
viral
replic
complex
mediat
synthesi
fulllength
negativestrand
rna
late
stage
chikv
replic
negativestrand
rna
direct
synthesi
positivestrand
genom
rna
requir
new
virion
format
product
structur
protein
postul
could
dual
block
effect
first
synthesi
chikv
nonstructur
viral
polyprotein
follow
secondari
inhibit
downstream
positivestrand
rna
synthesi
target
upstream
aug
codon
first
orf
block
translat
chikv
genom
rna
nonstructur
viral
polyprotein
inde
find
indic
signific
reduct
chikv
titr
knockdown
chikv
protein
synthesi
sustain
day
pi
suggest
suppress
nonstructur
protein
synthesi
earli
stage
chikv
replic
prior
day
pi
consequ
reduc
chikv
structur
protein
synthesi
infecti
virion
product
late
stage
chikv
replic
day
pi
hand
target
aug
region
second
orf
hinder
translat
chikv
subgenom
rna
structur
protein
name
capsid
therefor
like
exhibit
inhibitori
activ
late
stage
chikv
replic
inde
signific
reduct
chikv
titr
observ
day
pi
accompani
moder
decreas
protein
product
day
pi
experiment
timepoint
neg
sens
rna
product
could
occur
extens
may
suffici
effect
silenc
structur
protein
synthesi
consequ
inhibit
seen
lower
achiev
target
earli
step
chikv
replic
base
interpret
also
deduc
cpmo
sequencedepend
antivir
activ
control
scpmo
neither
caus
nonspecif
reduct
chikv
titr
drastic
decreas
protein
level
signifi
futur
studi
requir
specif
silenc
stage
chikv
replic
cpmo
candid
similarli
design
screen
order
confirm
strong
cellular
antichikv
efficaci
establish
treatment
regimen
chikvinfect
murin
model
neonat
mice
pretreat
follow
two
addit
dose
chikv
challeng
surviv
studi
demonstr
gg
confer
surviv
normal
daili
weight
gain
day
pi
contrast
pbsand
mice
suscept
chikv
diseas
mice
poor
weight
gain
paralysi
singl
hind
limb
day
pi
mortal
significantli
reduc
respect
end
two
week
murin
studi
report
chikv
primarili
infect
liver
muscl
joint
spleen
brain
display
tropism
characterist
chikv
pathogenesi
human
thu
murin
model
quantif
viremia
viru
load
examin
histopatholog
chang
necessari
investig
antivir
efficaci
found
viremia
significantli
reduc
log
mice
treat
gg
well
least
log
reduct
viru
load
spleen
liver
brain
limb
collect
skelet
muscl
hind
limb
liver
mice
display
healthi
tissu
morpholog
sign
chikvinduc
degen
damag
h
p
compar
gross
histopatholog
chang
strong
signal
chikv
antigen
distribut
observ
muscl
fibr
liver
tissu
pbsand
mice
consist
chikv
murin
model
establish
summari
find
provid
compel
evid
strong
efficaci
chikv
replic
postul
specif
translationalblock
activ
chikv
nonstructur
structur
protein
synthesi
exert
histolog
protect
mice
onset
chikv
pathogenesi
conclus
novel
studi
demonstr
strong
prophylact
efficaci
morpholino
oligom
inhibit
chikv
replic
cellbas
murin
model
find
may
necessari
evalu
robust
resist
viru
mutant
gener
well
therapeut
efficaci
administr
chikv
challeng
nevertheless
studi
reveal
proofofconcept
antivir
efficaci
sequencedepend
specif
morpholino
chikv
replic
long
run
evalu
requir
develop
morpholino
translat
antivir
therapi
chikv
diseas
chikv
use
cellular
infect
studi
genbank
viru
isol
serum
infect
patient
singapor
kindli
provid
environment
health
institut
nation
environment
agenc
singapor
chikv
lk
eh
genbank
use
mice
studi
establish
infecti
chikv
pool
confluent
monolay
cm
flask
infect
chikv
cell
maintain
media
fc
day
postinfect
pi
supernat
harvest
chikv
titr
determin
standard
viral
plaqu
assay
similarli
denv
strain
genbank
sinv
genbank
propag
cell
bhk
cell
respect
design
cpmo
genetool
usa
design
complementari
sequenc
locat
aug
region
chikv
genom
rna
viru
isol
genbank
fig
tabl
scrambl
morpholino
st
base
singapor
genetool
usa
random
base
sequenc
respect
cpmo
synthes
neg
control
visual
cellular
uptak
cytosol
distribut
cpmo
scpmo
coval
conjug
end
carboxyfluorescein
mice
studi
vivomorpholino
genetool
usa
name
scrambl
synthes
octaguanidin
dendrim
facilit
vivo
tissu
uptak
oligom
use
ncbi
blastn
tool
cpmo
align
publish
chikv
genom
sequenc
chikv
taxid
repres
geograph
isol
prototyp
centraleast
african
cea
genotyp
genbank
india
genbank
indonesia
genbank
singapor
genbank
sri
lanka
lk
eh
genbank
ecsa
genotyp
malaysia
bp
genbank
asian
genotyp
shown
fig
compar
sequenc
align
sinv
genbank
denv
genbank
also
perform
data
shown
assay
confluent
monolay
hela
cell
plate
treat
cpmo
premix
endoport
reagent
ad
cell
least
two
independ
treatment
triplic
carri
day
posttreat
hela
cell
wash
twice
pb
fix
paraformaldehyd
pb
permeal
tritonx
analysi
cpmo
distribut
chikvinfect
cell
cpmotreat
cell
infect
chikv
moi
day
posttreat
cell
fix
day
postinfect
fix
permeabil
describ
cell
incub
rabbit
antichikv
polyclon
antibodi
inhous
produc
dilut
follow
secondari
goat
antirabbit
dylight
dilut
thermoscientif
usa
antibodi
incub
perform
h
dilut
perform
pb
final
cell
nuclei
stain
dapi
duolink
situ
mount
media
sigmaaldrich
view
quantit
posit
signal
dapi
fitc
tritc
channel
magnif
olympu
invert
microscop
viral
plaqu
assay
bhk
cell
seed
confluenc
plate
quantif
infecti
viru
titr
harvest
cultur
supernat
mice
serum
homogen
organ
end
infect
cell
maintain
overlay
media
carboxymethyl
cellulos
media
supplement
fc
plate
incub
co
three
day
pi
chikv
infect
cell
stain
crystal
violet
dye
sinv
denv
titrat
cell
stain
crystal
violet
dye
two
day
pi
seven
day
pi
respect
viru
titr
quantit
number
plaqu
form
stain
monolay
western
blot
analysi
total
cell
lysat
harvest
day
pi
quantit
bca
assay
thermoscientif
g
lysat
subject
sdspage
chikv
protein
probe
use
rabbit
antichikv
polyclon
antibodi
inhous
produc
dilut
goat
antirabbit
secondari
antibodi
conjug
hrp
thermoscientif
dilut
scientif
report
doi
hand
chikv
protein
probe
use
rabbit
antibodi
inhous
produc
dilut
follow
secondari
antirabbit
hrp
antibodi
dilut
betaactin
detect
carri
use
mous
monoclon
antiactin
millipor
usa
chikv
blot
probe
antibodi
tbst
skim
milk
chikv
blot
probe
pbst
bsa
blot
wash
use
tb
pb
buffer
follow
incub
antibodi
protein
band
develop
enhanc
chemiluminesc
ecl
method
use
supersign
west
pico
chemiluminesc
substrat
thermoscientif
quantif
rel
band
densiti
perform
use
imag
j
follow
oneway
anova
analysi
refer
chikvinfect
control
band
transmiss
electron
microscopi
hela
cell
seed
confluenc
plate
treat
endoport
mocktreat
respect
h
posttreat
cell
wash
pb
infect
chikv
moi
day
pi
cell
fix
process
tem
describ
laboratoryestablish
protocol
ethic
statement
mice
experi
approv
perform
accord
guidelin
provid
institut
anim
care
use
committe
nation
univers
singapor
protocol
mice
treatment
neonat
balbc
mice
use
studi
anim
hous
pathogenfre
vivarium
cel
build
nation
univers
singapor
sixdayold
mice
n
per
group
treat
gg
gg
dilut
steril
pb
mocktreat
steril
pb
intraperiton
ip
inject
two
consecut
dose
everi
h
interv
h
follow
second
dose
mice
ip
inject
pfu
chikv
strain
lk
eh
genbank
h
h
pi
equival
dose
vivopmo
pb
given
endpoint
h
pi
mice
sacrif
anesthesia
whole
blood
brain
spleen
liver
limb
harvest
quantif
chikv
titr
tissu
homogen
use
precelli
ck
bead
centrifug
g
min
obtain
clarifi
supernat
viral
plaqu
assay
surviv
analysi
mice
n
pretreat
describ
follow
chikv
infect
mice
monitor
daili
score
sign
symptom
chikv
diseas
end
two
week
number
surviv
mice
note
mice
human
euthan
sacrif
toxic
evalu
vivopmo
mice
balbc
mice
old
n
ip
inject
steril
pb
gg
everi
h
day
h
last
treatment
mice
sacrif
whole
blood
collect
evalu
ldh
level
follow
manufactur
protocol
ldh
cytotox
assay
kit
biovis
usa
histolog
immunohistochem
examin
infect
mice
tissu
balbc
mice
old
n
pretreat
steril
pb
subject
chikv
infect
describ
day
pi
mice
sacrif
limb
liver
harvest
formalin
fix
dehydr
paraffin
embed
section
tissu
sampl
done
sampl
routin
stain
haematoxylin
eosin
h
e
ihc
tissu
sampl
label
primari
rabbit
antibodi
dilut
follow
secondari
goat
antirabbit
hrp
conjug
thermoscientif
assay
subsequ
perform
use
autom
bondmax
system
leica
biosystem
germani
base
custom
protocol
sever
step
dehydr
differenti
final
slide
mount
permounttm
mount
medium
fisher
chemic
uk
view
olympu
microscop
imag
captur
magnif
visual
chikv
antigen
